Beta Bionics (BBNX), a maker of insulin delivery devices, has disclosed terms for an upsized $113M initial public offering. In its latest SEC filing, the company said it was planning to offer 7.5M ...

To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Beta Bionics began trading on Thursday after filing to go public in early January. The diabetes technology ...

In addition, Beta Bionics sold 1,000,000 shares of its common stock in a concurrent private placement to one of its existing investors at the initial public offering price of $17.00 per share. The ...

Beta Bionics announces upsized IPO of 12 million shares at $17 each, aiming for $204 million in gross proceeds. Beta Bionics, Inc., a leader in diabetes management solutions, has announced the ...

Beta Bionics Inc., an Irvine-based medical device company, today began publicly trading on the Nasdaq Capital Market under the ticker BBNX. The company raised an upsized offering of $204 million by ...

Jan 22 (Reuters) - Insulin delivery device maker Beta Bionics said on Wednesday it was targeting a valuation of as much as $615.9 million in its initial public offering in the United States ...

Beta Bionics has set the terms for its plan to go public, with a goal of raising at least $114 million to support its artificial pancreas system for people with Type 1 diabetes. The California ...